Bone histomorphometry in untreated and treated glucocorticoid-induced osteoporosis

Frontiers of Hormone Research

Volumn 30, Issue , 2002, Pages 37-48

  Dalle Carbonare, L ^a,b   Chavassieux, P M ^a   Arlot, M E ^a   Meunier, P J ^a  

^a INSERM   (France)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID;

BONE; BONE DEVELOPMENT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATHOLOGY; REVIEW;

BONE AND BONES; BONE RESORPTION; GLUCOCORTICOIDS; HUMANS; OSTEOGENESIS; OSTEOPOROSIS;

EID: 0036359554     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000061069     Document Type: Article

References (34)

1. Lukert B: Glucocorticoid-induced osteoporosis; in Marcus R, Feldman D, Kelsey J (eds): Osteoporosis. San Diego, Academic Press, 1996, pp 801-820.
2. Klein RG, Arnaud SB, Gallagher JC, DeLuca HF, Riggs BL: Intestinal calcium absorption in exogenous hypercorticism: Role of 15-hydroxyvitamin D and corticosteroid dose. J Clin Invest 1977;60:253-259.
3. Suzuki Y, Ichikawa Y, Saito E, Homma M: Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32:151-156.
4. Adachi JD: Corticoid-induced osteoporosis. Am J Med Sci 1997;313:41-49.
5. Reid IR: Glucocorticoid-induced osteoporosis and other forms of secondary osteoporosis; in Meunier PJ (ed): Osteoporosis: Diagnosis and Management. London, Dunitz, 1998, pp 233-250.
6. Chavassieux P, Pastoureau P, Chapuy MC, Delmas PD, Meunier PJ: Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: A biochemical and histomorphometric study. Osteoporosis Int 1993;3:97-102.
7. Manolagas SC, Weinstein RS: New developments in the pathogenesis and treatment of steroidinduced osteoporosis. J Bone Miner Res 1999;14:1061-1066.
8. Bressot C, Meunier PJ, Chapuy MC, Lejeune E, Edouard C, Darby AJ: Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Relat Res 1979;1:303-311.
9. Meunier P, Courpron P, Edouard C, Bernard J, Bringuier J, Vignon G: Physiological senile involution and pathological rarefaction of bone. Clin Endocrinol Metab 1973;2:239-256.
10. Borelli A, Ribeiro Leite MO, Correa PHS, Jorgetti V, Marcondes JAM, Batalha JRF, Ulhôa Cintra AB, Wajchenberg BL: Bone histomorphometry in Cushing's syndrome. J Endocrinol Invest 1992; 15:783-787.
11. Dempster DW, Arlot MA, Meunier PJ: Mean wall thickness and formation period of trabecular bone packets in corticosteroids osteoporosis. Calcif Tissue Int 1983;35:410-417.
12. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, Hamdy NAT, Malice MP, Freedholm D, Meunier PJ: Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: A histomorphometric analysis of transiliac biopsies. J Bone Miner Res 2000; 15:754-762.
13. Stellon AJ, Webb A, Compston JE: Bone histomorphometry and structure in corticosteroid-treated chronic active hepatitis. Gut 1988;29:378-384.
14. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero N, Meunier PJ: Comparison of trabecular bone structure and microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 2001;16:97-103.
15. Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, Audran M: Altered trabecular architecture induced by corticosteroids: A bone histomorphometric study. J Bone Miner Res 1996;11:676-685.
16. Aaron JE, Francis RM, Peacock M, Makins NB: Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop 1989;243:294-305.
17. Mellish RWE, Ferguson-Pell MW, Cochran GVB, Lindsay R, Dempster DW: A new manual method for assessing two-dimensional cancellous bone structure: Comparison between iliac crest and lumbar vertebra. J Bone Miner Res 1991;7:689-696.
18. Vesterby A, Gundersen HJG, Melsen F: Star volume of marrow space and trabeculae of the first lumbar vertebra: Sampling efficiency and biological variation. Bone 1989;10:7-13.
19. Feldkamp LA, Goldstein SA, Parfitt AM, Jesion G, Kleerekoper M: The direct examination of three-dimensional bone architecture in vitro by computed tomography. J Bone Miner Res 1989; 4:3-11.
20. Hahn M, Vogel M, Pompesius-Kempa M, Delling G: Trabecular bone pattern factor - A new parameter for simple quantification of bone microarchitecture. Bone 1992;13:327-330.
21. Le HM, Holmes RE, Shors EC, Rosenstein DA: Computerized quantitative analysis of the interconnectivity of porous biomaterials. Acta Stereol 1992;11(suppl 1):267-272.
22. Weinstein RS, Majumdar S. Fractal geometry and vertebral compression fractures. J Bone Miner Res 1994;9:1797-1802.
23. Jowell PS, Epstein S, Fallon MD, Reinhardt TA, Ismail F: 1,25-Dihydroxyvitamin D3 modulates glucocorticoid-induced alteration in serum bone Gla protein and bone histomorphometry. Endocrinology 1987;120:531-536.
24. Dykman TR, Haralson KM, Gluck OS, Murphy WA, Teitelbaum SL, Hahn TJ, Hahn BH: Effects of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984;27:1336-1343.
25. Braun JJ, Birkenhäger-Frenkel DH, Rietveld AH, Juttman JR, Visser TJ, Birkenhäger JC: Influence of 1-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment: A double-blind controlled study. Clin Endocrinol 1983;18:265-273.
26. Conrozier T, Meunier PJ: Traitement de l'ostéoporose cortisonique par le fluore de sodium. Effects cliniques et données histomorphométriques. Ann Endocrinol 1985;46:369-370.
27. Meunier PJ, Briancon D, Chavassieux P, Edouard C, Boivin G, Conrozier T, Marcelli C, Pastoureau P, Delmas PD, Casez JP: Treatment with fluoride: Bone histomorphometric findings; in Christiansen C, Johansen JS, Riis BJ (eds): Osteoporosis 1987. Viborg, Norhaven, 1987, pp 824-828.
28. Nakamuta H, Nitta T, Hoshino T, Koida M: Glucocorticoid-induced osteopenia in rats: Histomorphometrical and microarchitectural characterization and calcitonin effect. Biol Pharm Bull 1996; 19:217-219.
29. Wimalawansa SJ, Simmons DJ: Prevention of corticosteroid-induced bone loss with alendronate. Proc Soc Exp Biol Med 1998;217:162-167.
30. Reid IR, King AR, Alexander CJ, Ibbertson HK: Prevention of steroid-induced osteoporosis with (3-amino-1-hydrohypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;i:143-146.
31. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104: 1363-1374.
32. Meunier PJ, Boivin G: Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications. Bone 1997;21:373-377.
33. Boivin GY, Chavasieux PM, Santora AC, Yates J, Meunier PJ: Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687-694.
34. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ: Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;15:1475-1480.